BioDiem Limited (BioDiem) is an Australia-based biopharmaceutical company. The Company is engaged in developing and commercializing vaccines and infectious disease therapies. BioDiem’s lead product, Live Attenuated Influenza Virus (LAIV) technology, is used to develop an intranasal vaccine for seasonal and pandemic influenza vaccines. The egg-based LAIV vaccine, Nasovac is used for protection against H1N1 influenza in India. The Company’s BDM-I is a compound, which is used against a range of pathogenic micro-organisms, including bacteria, fungi and protozoa. BioDiem is advancing BDM-I testing into pre-clinical models of infectious diseases, including schistosomiasis. The LAIV vector is used as a platform technology in the design of vaccines for different diseases, including cancers. Its BDM-E (epitalon) is used for the treatment of eye disorders, including Retinitis Pigmentosa (RP). The Company has a whollyowned subsidiary, Savine Therapeutics Pty Ltd.